USA Antibody Drug Conjugates Market Size, Share, Opportunities, And Trends By Target (CD 30, CD 22, HER 2), And By Indication (Hematologic Malignancies, Non- Hematologic Malignancies) - Forecast from 2022 To 2027

Description

USA Antibody Drug Conjugates Market Size:

The USA antibody drug conjugates market is projected to witness a compound annual growth rate of 24.16% during the forecast period.

USA Antibody Drug Conjugates Market Trends:

The prime reasons driving the market growth of antibody-drug conjugates in the country are the surging cases of cancer and the rise in medical expenditure. Antibody drug conjugates are a cutting-edge cancer treatment that offers a promising and successful approach.  Surging cancer cases in the country are expected to be the prime reason that will drive the market growth. However, rising medical costs and a surge in medical tourism have the potential to limit the market demand. The analysis report segments the market for USA Antibody Drug Conjugates technology based on target and indication.

By target, the USA antibody drug conjugates market has been segmented into CD30, CD22, and HER2. CD 30 is expected to hold a notable share of the market during the forecasted period. By indication, the market has been segmented into hematologic malignancies and non-hematologic malignancies.

USA Antibody Drug Conjugates Market Growth Factors:

• Rising cancer cases in the US

One of the prime reasons supporting the growth in the USA Antibody Drug Conjugates market is the rising cancer cases in the country, which has increased the demand for antibody-drug conjugates. Data from the American Cancer Society shows that 1.9 million new cancer cases were diagnosed in the country in 2021. In 2018, 1.7 million new cancer cases were discovered. The rising cases, coupled with an increasing number of cases year on year, have raised concerns in the country. The increasing standard of living and rising healthcare expenditure have increased the expenditure on treatments and, hence, are forecasted to provide a notable scope for antibody-drug conjugates.

• Increasing healthcare spending

Another key reason that is forecasted to drive robust growth in the market is surging healthcare expenditure in the country. The US has one of the largest healthcare sectors in the world, with state-of-the-art infrastructure and advanced technology. The growing prevalence of chronic diseases and a surge in cancer cases have increased government expenditure in the sector. The government had spent 19.7% of the country’s GDP, accounting for US$4.1 trillion in 2020. It is further forecasted that the government’s sector expenditure will surge to US$6.2 trillion by 2028. Promising growth in the healthcare sector is expected to drive notable demand for antibody drug conjugates in the country.

USA Antibody Drug Conjugates Market Restraints:

• Growing medical tourism

A key restraint facing the market is rising medical tourism, which drives away the potential demand for antibody drug conjugates in the country. Healthcare costs per person in the country are significant, consuming a large portion of earnings.  The growing advent of diseases and surging healthcare costs has notably increased private healthcare expenditure, from 49.301% of healthcare expenditure in 2015 to 49.587% in 2018. Surging healthcare bills, coupled with the availability of pocket-friendly healthcare tourism, have driven medical tourists to countries such as Mexico, China, India, South Korea, Thailand, and others. This has notably impacted the market for antibody-drug conjugates.

USA Antibody Drug Conjugates Market Scope:

USA Antibody Drug Conjugates Market Segmentation:

• By Target
  • CD 30
  • CD 22
  • HER 2
• By Indication
  • Hematologic Malignancies
  • Non- Hematologic Malignancies

Table Of Contents

1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY  
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. USA ANTIBODY DRUG CONJUGATES MARKET,  BY TARGET 
5.1. Introduction
5.2. CD 30
5.3. CD 22
5.4. HER 2
6. USA ANTIBODY DRUG CONJUGATES MARKET, BY INDICATION
6.1. Introduction
6.2. Hematologic Malignancies
6.3. Non- Hematologic Malignancies
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. Takeda Pharmaceutical Company Limited
8.2. F. Hoffmann-La Roche Ltd.
8.3. Pfizer Inc.
8.4. Astellas Pharma Inc.
8.5. Seattle Genetics, Inc. *List is not exhasutive

Companies Profiled

Takeda Pharmaceutical Company Limited

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

Astellas Pharma Inc.

Seattle Genetics, Inc.

Related Reports